Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27996077 | 0.93 | CA12 (0.42) | SLC7A5KDM4ECA12CA1CA2 | |
| SCHEMBL1767847 | 0.87 | KDM4E (0.40) | SLC7A5KDM4ECA12CA1CA2 | |
| SCHEMBL7074918 | 0.87 | KDM4E (0.56) | SLC7A5KDM4ECA12CA1CA2 | |
| SCHEMBL7071957 | 0.85 | CYP3A4 (0.46) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL7078434 | 0.85 | HSD17B10 (0.42) | SLC7A5KDM4ECA12CA1CA2 | |
| SCHEMBL7075526 | 0.85 | KEAP1 (0.42) | SLC7A5KDM4ECA12CA1CA2 | |
| SCHEMBL27481746 | 0.81 | SLC7A5 (0.41) | SLC7A5KDM4ECA12CA1CA2 | |
| SCHEMBL3119361 | 0.80 | CA12 (0.36) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL16114294 | 0.79 | GRM6 (0.40) | SLC7A5KDM4ECA12CA1CA2 | |
| SCHEMBL29594182 | 0.79 | KDM4E (0.39) | SLC7A5KDM4ECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117209887-B | High-toughness durable polypropylene material and preparation process thereof | 珠海市金塑塑料有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-117209887-A | High-toughness durable polypropylene material and preparation process thereof | 广东科净塑料制品有限公司 | 2023-12-12 | — | — | CN | claimed |
| US-20250108139-A1 | PEPTIDE UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE UREA DERIVATIVE, AND APPLICATION OF PEPTIDE UREA DERIVATIVE | BIVISION PHARMACEUTICALS, INC (CN) | 2025-04-03 | — | — | US | disclosed |
| EP-4474379-A1 | PEPTIDE UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE UREA DERIVATIVE, AND APPLICATION OF PEPTIDE UREA DERIVATIVE | Bivision Pharmaceuticals, Inc (CN) | 2024-12-11 | — | — | EP | disclosed |
| CN-117209887-B | High-toughness durable polypropylene material and preparation process thereof | 珠海市金塑塑料有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117209887-A | High-toughness durable polypropylene material and preparation process thereof | 广东科净塑料制品有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023143612-A1 | PEPTIDE UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE UREA DERIVATIVE, AND APPLICATION OF PEPTIDE UREA DERIVATIVE | 晶核生物医药科技(南京)有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116514735-A | Peptide urea derivative, pharmaceutical composition containing same and application of peptide urea derivative | 晶核生物医药科技(南京)有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-9250525-B2 | Resist underlayer film-forming composition | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150362838-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL IND LTD (JP) | 2015-12-17 | — | — | US | disclosed |
| US-9212255-B2 | Resist underlayer film-forming composition | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150087155-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-03-26 | — | — | US | disclosed |
| EP-1259532-B1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING SPA (IT) | 2005-05-04 | — | — | EP | disclosed |
| US-6803030-B2 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | BRACCO IMAGING S.P.A. (IT) | 2004-10-12 | — | — | US | disclosed |
| US-20030113265-A1 | Bile acids conjugates with metal ion chelates and the use thereof | BRACCO IMAGING S.P.A. (IT) | 2003-06-19 | — | — | US | disclosed |
| EP-1259532-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | Bracco Imaging S.p.A. (IT) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001064708-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING S.P.A. (IT) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108139-A1 | PEPTIDE UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE UREA DERIVATIVE, AND APPLICATION OF PEPTIDE UREA DERIVATIVE | UROD, PSMA1, PSMA3 | SLC7A5 2080/4885KDM4E 3365/4885CA12 315/4885 |
| US-20030113265-A1 | Bile acids conjugates with metal ion chelates and the use thereof | SLC10A2, SLC10A1, NR1H4 | SLC7A5 26/4885KDM4E 4723/4885CA12 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.